Any current/future new fundraising through debt or equity?

No explicit mention of any current or future fundraising through debt or equity in the transcript. The company expects insurance payouts (~Rs. 100 crore) to start coming in December-January, which will help reduce debt. Operational cash flow generation is improving, aiding debt reduction. The company is funding CAPEX (~Rs. 200 crore over two years) largely from internal accruals and insurance reimbursements. No indications or plans were discussed regarding raising funds via equity or additional debt during the call.

Any current/future capex/capital investment/strategic investment?

Total CAPEX planned around Rs. 200 crore over this and next year, including growth and reinstatement projects. Rs. 47 crore CAPEX done in H1 FY25, with approx. Rs. 50 crore expected in H2 FY25 and another Rs. 50 crore in H1 FY26. Major part (around Rs. 100 crore) for Vashivali factory rebuild due to fire incident. Additional Rs. 50 crore to Rs. 60 crore incremental CAPEX expected post insurance reimbursement. Building two new factories domestically and proposing a new factory in Europe (~Rs. 45-50 crore each). European manufacturing capacity near 75-80% utilization; plans for one or two new Eu

Future growth expectations in sales/revenue/volumes?

The company expects second half FY25 revenue growth to be better than the first half, targeting around 14% full-year growth, exceeding the midterm CAGR target of 12%. Growth guidance for FY26 and FY27 remains intact with continued momentum. Strong growth is driven by small and mid-sized customers (40% growth contribution) and global accounts (40%). New Creative Development Centres in Germany and UK will start contributing meaningful revenue in 6-8 months, supporting future growth beyond 12%. Investments in Europe and America are expected to pay off in coming years, enhancing global pre

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects to achieve a 20% EBITDA margin within the next 2-3 years, up from the current adjusted margin of around 16-18.5%, after accounting for ongoing investments in new growth areas. Investments in new Creative Development Centres in Europe (Germany, Manchester) and America will start generating meaningful revenue in 6-8 months, supporting future growth. Revenue growth is expected to be above 12% CAGR with a stronger second half for FY25, driven by contributions from small and mid-sized customers and global MNC accounts. Insurance payouts related to recent fire incidents are

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention specific figures or details about the current or expected order book or pending orders. However, it highlights a strong top-line performance driven by steady momentum in small and mid-sized customers and execution of prestigious global MNC orders. There is mention of clearing backlog from previous disruptions, implying pending orders were addressed. Growth is supported by new global accounts and expansion in various markets, including Europe and the US. The company anticipates better second half performance with strategic initiatives contributing to o

S H Kelkar & Co.Q2 FY25Chemicals & Petrochemicals

S H Kelkar & Co. Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹138P/E: 41.7Market Cap: ₹2.0K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company expects second half FY25 revenue growth to be better than the first half, targeting around 14% full-year growth, exceeding the midterm CAGR target of 12%.
Growth guidance for FY26 and FY27 remains intact with continued momentum.
Strong growth is driven by small and mid-sized customers (40% growth contribution) and global accounts (40%).
New Creative Development Centres in Germany and UK will start contributing meaningful revenue in 6-8 months, supporting future growth beyond 12%.
Investments in Europe and America are expected to pay off in coming years, enhancing global presence.
India operations to double capacity; Europe to add 50% capacity over the next two years facilitating volume growth.
The company is cautiously optimistic pending global economic changes but sees opportunities arising from shifts in the supply chain and tariffs.

Margin guidance

Category 3

The company expects to achieve a 20% EBITDA margin within the next 2-3 years, up from the current adjusted margin of around 16-18.5%, after accounting for ongoing investments in new growth areas.
Investments in new Creative Development Centres in Europe (Germany, Manchester) and America will start generating meaningful revenue in 6-8 months, supporting future growth.
Revenue growth is expected to be above 12% CAGR with a stronger second half for FY25, driven by contributions from small and mid-sized customers and global MNC accounts.
Insurance payouts related to recent fire incidents are expected by December-January, improving cash flow and reducing debt.
Incremental investments in R&D and production capacity are expected to taper, enabling margin expansion as revenues from these investments ramp up.
Overall, sustained volume-led growth, product mix improvements, and strategic international expansion underpin positive earnings and profit outlook.

See what S H Kelkar & Co. management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any current or future fundraising through debt or equity in the transcript.
The company expects insurance payouts (~Rs. 100 crore) to start coming in December-January, which will help reduce debt.
Operational cash flow generation is improving, aiding debt reduction.
The company is funding CAPEX (~Rs. 200 crore over two years) largely from internal accruals and insurance reimbursements.
No indications or plans were discussed regarding raising funds via equity or additional debt during the call.

Order book

Yes

The transcript does not explicitly mention specific figures or details about the current or expected order book or pending orders.
However, it highlights a strong top-line performance driven by steady momentum in small and mid-sized customers and execution of prestigious global MNC orders.
There is mention of clearing backlog from previous disruptions, implying pending orders were addressed.
Growth is supported by new global accounts and expansion in various markets, including Europe and the US.
The company anticipates better second half performance with strategic initiatives contributing to order flow.
Opportunities are expected from geopolitical shifts, such as potential tariff changes in the US that may favor Indian suppliers over Chinese ones, which could translate to new orders.
Overall, order visibility appears positive with ongoing investments to support future growth and capacity expansion.

See what S H Kelkar & Co. management said on order book — free account, 30 seconds.

Capex plans

Yes

Total CAPEX planned around Rs. 200 crore over this and next year, including growth and reinstatement projects.
Rs. 47 crore CAPEX done in H1 FY25, with approx. Rs. 50 crore expected in H2 FY25 and another Rs. 50 crore in H1 FY26.
Major part (around Rs. 100 crore) for Vashivali factory rebuild due to fire incident.
Additional Rs. 50 crore to Rs. 60 crore incremental CAPEX expected post insurance reimbursement.
Building two new factories domestically and proposing a new factory in Europe (~Rs. 45-50 crore each).
European manufacturing capacity near 75-80% utilization; plans for one or two new European factories over next 2-3 years.
Closure planned for Mulund factory after new factories come online, leading to OPEX savings.
Investments include Creative Development Centres: Germany and Manchester operational; new US center starting with gradual investment ramp-up.
Annual recurring additional OPEX of around Rs. 20 crore in employee and operational costs for development centers.

Track S H Kelkar & Co. — get its next earnings analysis in your feed

How does S H Kelkar & Co. rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisS H Kelkar & Co.

Rev 3Mar 3

See where S H Kelkar & Co. sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does S H Kelkar & Co. rank in Chemicals & Petrochemicals?

Compare S H Kelkar & Co. against every Chemicals & Petrochemicals company (Q2 FY25) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What S H Kelkar & Co.'s management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

S H Kelkar & Co. Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does S H Kelkar & Co. rank in Chemicals & Petrochemicals?

Continue your research

What S H Kelkar & Co.'s management said in earlier quarters

Others in Chemicals & Petrochemicals this season